Dayna Williams

On July 9, 2026, the FDA approved subcutaneous isatuximab-irfc (Sarclisa Escena), administered via an on-body injector or manual subcutaneous injection, across all previously approved isatuximab indications in multiple myeloma.The agent was approved in combination with pomalidomide (Pomalyst) and dexamethasone in multiple myeloma after at least 1 prior therapy including lenalidomide (Revlimid) and a proteasome inhibitor; carfilzomib (Kyprolis) and dexamethasone in relapsed/refractory disease...

Combining eftilagimod alfa (efti) with pembrolizumab (Keytruda) and chemotherapy produced positive overall survival (OS) data as frontline treatment for patients with advanced or metastatic non–small cell lung cancer (NSCLC), according to a press release on findings from the phase 1 INSIGHT-003 trial (NCT03252938).1 What did data from the INSIGHT-003 trial show?

Adding subablative radiotherapy to ipilimumab (Yervoy) and nivolumab (Opdivo) induced objective clinical responses in a small subset of patients with metastatic non–small cell lung cancer (NSCLC) and low or negative PD-L1 expression who had progressed on first-line anti–PD-1 therapy, according to findings from the phase 2 RECLAIM trial (EudraCT 2020-001097-29) published in the Journal for ImmunoTherapy of Cancer.